α-硫辛酸联合莫沙必利对糖尿病性胃轻瘫患者的临床疗效和不良反应的观察

Clinical efficacy and safety of alpha-lipoic acid combined with mosapride in treatment of diabetic gastroparesis

目的探讨莫沙必利联合α-硫辛酸治疗糖尿病性胃轻瘫临床疗效.方法选取2015-08/2017-02华中科技大学同济医学院附属梨园医院收治的糖尿病性胃轻瘫患者92例,根据随机数表法随机分为观察组和对照组,各46例,两组均给予降糖、运动等常规治疗,对照组患者给予莫沙必利治疗,观察组患者在此基础上给予α-硫辛酸联合治疗,2 wk为1疗程.对两组患者治疗疗效进行比较,并比较两组患者治疗前后胃动素和胃排空率、不良反应等指标.结果治疗后,观察组总有效率显著优于对照组(93.48%vs84.78%),两组疗效差异明显(P<0.05);治疗前,两组患者胃动素和胃排空率无差异,治疗后,两组胃动素和胃排空率均有改善,且观察组幅度更加明显(P<0.05);观察组不良反应发生率显著低于对照组(4.35%vs13.04%),差异显著(P<0.05).结论莫沙必利联合α-硫辛酸治疗糖尿病性胃轻瘫临床疗效显著,促进胃排空,纠正胃肠激素,且不良反应较少,值得临床进一步推广.

AIM To evaluate the clinical efficacy and safety of alphalipoic acid combined with mosapride in the treatment of diabetic gastroparesis. METHODS Ninety-two patients with diabetic gastroparesis treated at our hospital from August 2015 to February 2017 were randomly divided into either an observation group or a control group, with 46 cases in each group. Both groups were given conventional treatment and mosapride, and the observation group was additionally given alpha lipoic acid. After 2 wk of treatment, the curative effect, gastric motilin, gastric emptying, and adverse reactions were compared between the two groups. RESULTS The total effective rate was significantly higher in the observation group than in the control group （93.48% vs 84.78%, P 〈 0.05）. Before treatment, there was no difference in gastric motilin or gastric emptying rate between the two groups. After treatment, both groups showed a significant decrease in gastric activity and a significant increase in gastric emptying rate （P 〈 0.05）, and the changes were more significant in the observation group （P 〈 0.05）. The incidence of adverse reactions in the observation group was significantly lower than in the control group （4.35% vs 13.04%, P 〈 0.05）. CONCLUSION Alpha-lipoic acid combined with mosapride has remarkable clinical efficacy in treating diabetic gastroparesis, and can promote gastric emptying and correct gastrointestinal hormones, with few adverse reactions.